Most Read Cancer Science & Oncogenesis +...

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260529 Triple-negative breast cancer: current understanding and future perspectives. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the absence of estrogen receptors, progesterone receptors, and human epid.. 2026: Exploration of targeted anti-tumor therapy.

Interprofessional Approach to Adverse Event Care for the Patient With High-Risk Hormone Receptor-Positive/HER2-Negative Early Breast Cancer Authors: Jonathan Malara, PharmD, BCOP; Nelli Zafman, CRNP, MSN, AOCNP

https://www.medscape.org/viewarticle/interprofessional-approach-adverse-event-care-patient-high-2026a1000gez?page=1

Fact vs. Fallacy: Challenging the Norms of Cancer Care Fallacies in Medicine Bishal Gyawali, MD, PhD

https://www.medscape.com/viewarticle/fact-vs-fallacy-challenging-norms-cancer-care-fallacies-2026a1000gei Hello, everyone. This is Dr Bishal Gyawali, from Queens University, Kingston, Canada. Today, I’m back with you to talk about some of the fallacies that I have seen in medicine, oncology, and the drug regulatory space. I wanted to clarify some of these fallacies.

American Society of Clinical Oncology (ASCO) 2026

https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g

Which Patients With Early HCC Should Undergo Resection? Daniela Barros l Medscape Europe May 29, 2026

https://www.medscape.com/viewarticle/which-patients-early-hcc-should-undergo-resection-2026a1000hwk For years, patients with early-stage hepatocellular carcinoma (HCC) who had multiple liver nodules were typically referred for less-invasive locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). The logic seemed sound: to avoid surgical trauma in people who often already have cirrhosis or limited liver function. Now, a new national multicenter meta-analysis suggests that, in carefully selected patients, this approach may need to be reconsidered.

CAR-T Therapy Shows Promise in CNS and Extramedullary B-ALL Edited by Gargi Mukherjee May 29, 2026

https://www.medscape.com/viewarticle/car-t-therapy-shows-promise-cns-and-extramedullary-b-all-2026a1000hyx CD19 chimeric antigen receptor (CAR) T-cell therapy achieved high response rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and extramedullary disease or central nervous system (CNS) involvement, according to a retrospective review. More than 80% of patients achieved clearance of their extramedullary or CNS disease; however, patients with concurrent high bone marrow disease burden experienced significantly worse survival than those with low bone marrow burden.

A single viral platform shows promise across infectious disease and cancer ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer. Written byBree Foster, PhD

A single viral platform shows promise across infectious disease and cancer ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer. Written byBree Foster, PhD https://www.drugdiscoverynews.com/a-single-viral-platform-shows-promise-across-infectious-disease-and-cancer-17103?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_Tdx3m2iMvdp1D3k42S5hPo1PrPtt3IjBfdsUwgZ-0LEAiv-XA5590T3h9k7W1V0wPFzJZ4rS9-snPUOaMSLUTIou5bg&_hsmi=421171733&utm_content=421171733&utm_source=hs_email At Advanced Therapies 2026, DDN spoke with Claudio Panzarella, Head of Business Development, and Angelo Raggioli, Head of Technology Development, at ReiThera, about how the company’s early COVID-19 vaccine efforts shaped its current scientific programs, including the gorilla adenovirus (GRAd) platform, ongoing HIV vaccine trials, and the potential for oncology therapeutics.